Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 91.02M P/E - EPS this Y 9.70% Ern Qtrly Grth -
Income -47.92M Forward P/E -1.42 EPS next Y 9.80% 50D Avg Chg 2.00%
Sales 10.09M PEG - EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 0.84 EPS next 5Y - 52W High Chg -36.00%
Recommedations 2.60 Quick Ratio 3.94 Shares Outstanding 41.15M 52W Low Chg 140.00%
Insider Own 7.75% ROA -34.28% Shares Float 15.86M Beta 2.53
Inst Own 68.08% ROE -66.10% Shares Shorted/Prior 163.98K/189.29K Price 2.29
Gross Margin - Profit Margin - Avg. Volume 138,196 Target Price 2.75
Oper. Margin -386.70% Earnings Date May 13 Volume 75,018 Change 1.33%
About Spruce Biosciences, Inc.

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Spruce Biosciences, Inc. News
03:05 PM Spruce Biosciences to Participate in May Investor Conferences
04/30/24 Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
04/22/24 Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
03/27/24 Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
03/23/24 Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)
03/21/24 Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
03/16/24 Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price
03/13/24 Spruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial Setbacks
03/13/24 Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
03/13/24 Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
01/30/24 Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/22/24 Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
01/05/24 Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
01/04/24 Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
11/13/23 Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
11/02/23 Spruce Biosciences to Participate in the Jefferies London Healthcare Conference
10/18/23 Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study in Adult Classic Congenital Adrenal Hyperplasia
08/28/23 Spruce Biosciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08/14/23 Spruce Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
07/24/23 Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
SPRB Chatroom

User Image HuntingBenjmins Posted - 11 minutes ago

$SPRB Hopefully in the upcoming fireside chats they have some good things to say.

User Image Stock_Titan Posted - 5 hours ago

$SPRB Spruce Biosciences to Participate in May Investor Conferences https://www.stocktitan.net/news/SPRB/spruce-biosciences-to-participate-in-may-investor-uu80jd75d2op.html

User Image Tshanky_ Posted - 9 hours ago

$SPRB @Gunnar1 got me on this.

User Image King_Ranger Posted - 10 hours ago

$SPRB LETS GOOOOOOO

User Image Trade4Lobsters Posted - 11 hours ago

$SPRB Let’s gooo!! $LABU $XBI

User Image Pberry Posted - 11 hours ago

$SPRB perking up?

User Image Billianas Posted - 15 hours ago

$SPRB bearish penant… target 0,50$ - 0,55$ keep it on watch!

User Image lqqkerinsiderDOTcom Posted - 04/30/24

$SPRB ADDED MORE 2DAY! I ❤ this lil CASH COOKIE 🍪

User Image Stock_Titan Posted - 04/30/24

$SPRB Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting https://www.stocktitan.net/news/SPRB/spruce-biosciences-announces-additional-poster-presentation-at-the-wm8kqairzwf3.html

User Image wildwood10 Posted - 04/30/24

$SPRB added

User Image Moneytimeeeeee Posted - 04/30/24

$ELWS $GDHG $SPRB

User Image Gunnar1 Posted - 04/30/24

$SPRB At current level SPRB is like $ATRA in the high 0.4's or $ACRS in the 0.8's (both after their gap downs last year). Just my opinion.

User Image DJS777 Posted - 04/29/24

$GDHG $ELWS both looking great atm , also in on $SPRB small float good financials amd float plus insiders owning solid 2 swings imho

User Image INTS915 Posted - 04/29/24

$SPRB , same old crappy 💩 data.

User Image dipbuyer23 Posted - 04/26/24

$SPRB

User Image dipbuyer23 Posted - 04/26/24

$SPRB more funds buying

User Image Emxc2 Posted - 04/25/24

$SPRB i'm holding, patience pays off...like my CYN and KINTARA and CERO in recent weeks

User Image Trade4Lobsters Posted - 04/25/24

$SPRB We all still buying or what? Seems like still a great opportunity here.

User Image dipbuyer23 Posted - 04/24/24

$SPRB still a lot of selling. Need more buyers. This will rip with any good news

User Image Pberry Posted - 04/24/24

$SPRB

User Image Gunnar1 Posted - 04/24/24

$SPRB This is the abstract that was accepted for poster presentation at the PES Annual Meeting (May 3):

User Image dontsmile Posted - 04/24/24

$SPRB launch it 🧨

User Image Gunnar1 Posted - 04/23/24

$SPRB Daily chart. Similar pattern so far like last Oct/Nov. If history repeats, there will be some climbing over the next weeks. We'll see, of course there are no guarantees. Important: they have cash until the end of 2025, including beyond anticipated topline results from CAHmelia-204 and additional dose-ranging data from CAHptain-205.

User Image INTS915 Posted - 04/23/24

$SPRB , same old data presentation. This will tank below 0.60 soon.

User Image Pberry Posted - 04/23/24

$SPRB

User Image Corona_My_Sharona Posted - 04/23/24

$SPRB,,,,,,,,,,,, https://www.forbes.com/sites/jakezamansky/2013/08/08/the-great-vampire-squid-keeps-on-sucking/?sh=47c5415e7df8

User Image INTS915 Posted - 04/23/24

$SPRB , no way....

User Image Pberry Posted - 04/23/24

$SPRB can we see .80

User Image Pberry Posted - 04/23/24

$SPRB

User Image INTS915 Posted - 04/23/24

$SPRB, nothing new. Same data, which released few months back and share tanked 80 %.

Analyst Ratings
RBC Capital Sector Perform Mar 14, 24
HC Wainwright & Co. Neutral Mar 14, 24
Leerink Partners Market Perform Mar 14, 24
JMP Securities Market Outperform Mar 14, 24
Ladenburg Thalmann Neutral Mar 14, 24
Guggenheim Neutral Mar 14, 24
RBC Capital Outperform Mar 5, 24
RBC Capital Outperform Feb 26, 24
Guggenheim Buy Feb 21, 24